Last Updated: November 19, 2026

List of Excipients in Branded Drug IODIXANOL

« Back to Dashboard


Iodixanol Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: October 29, 2026

Iodixanol is a mature, nonionic, iso-osmolar iodinated contrast medium marketed primarily as Visipaque by GE HealthCare. Its commercial value is concentrated in injectable formulation performance, supply reliability, hospital purchasing, and regulatory execution rather than in basic composition-of-matter exclusivity. The main excipient opportunity is to improve stability, container compatibility, sterilization robustness, and manufacturing economics without changing the product's approved clinical profile.

What is the formulation of iodixanol and which excipients does it contain?

Iodixanol injection is a sterile, aqueous formulation containing the active contrast agent, tromethamine, calcium disodium edetate, hydrochloric acid for pH adjustment, and water for injection. The marketed strengths include 270 mg iodine/mL and 320 mg iodine/mL formulations in the United States (FDA, 2023).

Component Functional role Commercial relevance
Iodixanol Nonionic X-ray contrast agent Drives viscosity, osmolality, iodine concentration, and dose economics
Tromethamine Buffer and pH-control agent Supports formulation stability and injectable pH
Calcium disodium edetate Chelating agent Binds trace metals that can promote degradation or discoloration
Hydrochloric acid pH adjustment Controls final formulation pH
Water for injection Vehicle Determines sterility, endotoxin control, and container compatibility

The formulation is designed to be iso-osmolar with blood at clinically relevant concentrations. That property differentiates iodixanol from many low-osmolar contrast agents, but it also creates formulation constraints. Iodixanol solutions have high dissolved-solute loads and can have substantial viscosity, particularly at 320 mg iodine/mL. Any excipient change must preserve injectability, osmolality, pH, chemical stability, visual clarity, and compatibility with automated contrast injectors.

The label identifies no antimicrobial preservative. The product is supplied as a sterile, single-use or pharmacy-controlled injectable presentation, making container closure integrity and aseptic manufacturing central to the quality strategy (FDA, 2023).

What excipient functions are most important for iodixanol?

The highest-value excipient functions are metal control, pH stability, and control of solution properties.

Metal-ion control

Trace metals can catalyze degradation pathways, affect color, or compromise long-term stability. Calcium disodium edetate is therefore more than a conventional inactive ingredient. It is a chemical-stability control and may be difficult to replace without comparative extractables, leachables, and stability data.

Potential commercial alternatives include other pharmaceutically acceptable chelators, but substitution would require evaluation of:

  • Chelation strength across the product's pH range
  • Compatibility with iodixanol and packaging materials
  • Toxicological acceptability for intravenous administration
  • Impact on osmolality and conductivity
  • Stability under terminal sterilization or aseptic processing
  • Compatibility with compendial and regulatory requirements

A replacement chelator could create a formulation patent opportunity if it produces a measurable stability or manufacturing advantage. The commercial barrier is the need to establish equivalence or superiority without altering the clinical safety profile.

Buffering and pH control

Tromethamine maintains formulation pH and may reduce degradation during storage. Buffer selection affects:

  • Degradation rate
  • Container interaction
  • Particulate formation
  • Injection tolerability
  • Osmolality
  • Sterilization performance

A new buffer system could support a differentiated product only if it improves shelf life, reduces manufacturing variability, or enables a lower-cost process. A simple substitution of tromethamine is unlikely to produce durable market protection because excipient changes are generally easy for competitors to design around unless supported by narrow, technically defensible claims.

Viscosity and injectability

Iodixanol's high concentration contributes to clinically useful iodine delivery but also creates a viscosity burden. Excipient systems that reduce viscosity without lowering iodine concentration could have commercial value in:

  • CT angiography
  • Cardiac catheterization
  • Power-injector use
  • Pediatric imaging
  • High-throughput radiology departments

A viscosity-reducing excipient must not increase osmolality, alter iodine availability, induce precipitation, or create compatibility problems with syringes, tubing, and automated injectors. A successful formulation could support method-of-use, composition, and device-compatibility claims.

What patents protect iodixanol products?

Iodixanol's original active-ingredient and product-development patents are mature and are not the principal source of current commercial exclusivity. The relevant protection categories are:

  1. Iodixanol composition-of-matter patents.
  2. Processes for synthesizing and purifying iodixanol.
  3. Injectable formulations.
  4. Specific concentrations and dosing regimens.
  5. Container and delivery systems.
  6. Manufacturing and quality-control processes.

The original iodixanol product was developed by Nycomed, later acquired through corporate transactions involving Amersham and GE HealthCare. Product branding and regulatory ownership are distinct from the identity of the original patent applicant.

Protection category Expected status for a mature iodixanol product Current commercial value
Active ingredient Generally expired in major markets Low as a blocking right
Original formulation Generally expired or near-expired Low to moderate
Manufacturing process Potentially active only for later improvements Moderate if difficult to design around
Excipient combination Relevant only for later-filed claims Moderate
Container or injector compatibility May support narrow claims Moderate
Method of use Potentially relevant for specific imaging procedures Low to moderate
Trade secrets May remain valuable indefinitely High for process know-how

A complete live patent opinion requires a jurisdiction-specific search of issued claims, terminal disclaimers, maintenance fees, reexamination history, and patent-family status. Patent publication alone does not establish an enforceable blocking right.

What is the Orange Book status of iodixanol?

The FDA Orange Book identifies approved drug products and, where applicable, listed patents and regulatory exclusivities. For a mature injectable product such as Visipaque, the key diligence questions are:

  • Whether the reference product has current listed patents.
  • Whether any listed patent has an expiration date that could delay an ANDA.
  • Whether the applicant must make a Paragraph IV certification.
  • Whether the product is eligible for a suitability petition or requires a full ANDA.
  • Whether the proposed generic matches the reference product in strength, dosage form, route, and inactive-ingredient profile.

Iodixanol is a small-molecule injectable, not a biologic. Biosimilar pathways do not apply. A competing manufacturer would generally pursue an ANDA if it can demonstrate pharmaceutical equivalence and bioequivalence or satisfy the applicable injectable-product requirements.

The absence of a current blocking patent would not eliminate commercial barriers. Injectable contrast products require validated sterile manufacturing, high-quality analytical methods, container-closure testing, particulate control, and reliable supply of a high-value active pharmaceutical ingredient.

When does iodixanol lose exclusivity?

Iodixanol's primary statutory exclusivity has long expired because the U.S. product was approved in the 1990s. The practical loss of exclusivity occurred through the expiration of original active-ingredient and formulation protection, not through the end of a remaining new chemical entity period.

Milestone Approximate timing or status
U.S. approval of Visipaque 1990s
New chemical entity exclusivity Expired
Original composition protection Mature and generally expired
Current competition Limited by technical and commercial barriers rather than basic exclusivity
Generic-entry strategy ANDA, subject to Orange Book and product-specific requirements

The commercial question is therefore not whether the core molecule remains protected. It is whether a competitor can manufacture an equivalent sterile injectable at a cost and quality level acceptable to hospitals, group purchasing organizations, distributors, and radiology departments.

What Paragraph IV challenges and generic-entry risks affect iodixanol?

A Paragraph IV certification is relevant only when an ANDA applicant addresses an Orange Book-listed patent by asserting that the patent is invalid, unenforceable, or not infringed. The business impact depends on whether the reference product has a live, listed patent and whether the patent owner files suit within the statutory period.

For iodixanol, the principal generic-entry risks are operational:

  • High active-ingredient cost
  • Limited qualified API suppliers
  • Complex synthesis and purification
  • High solution viscosity
  • Sterile manufacturing capacity
  • Low tolerance for visible or subvisible particulate matter
  • Regulatory scrutiny of inactive ingredients
  • Hospital contracting and supply continuity
  • Need for multiple package sizes and concentrations

A generic manufacturer may enter with the same concentration and excipient profile to reduce regulatory risk. A differentiated manufacturer may pursue a formulation with improved viscosity, shelf life, packaging, or injector performance. The first approach is faster and less patent-intensive. The second can support product differentiation but requires a larger development program.

What formulation patents could create commercial opportunities?

The strongest prospective patent opportunities are narrow, measurable improvements rather than broad claims covering iodixanol with conventional excipients.

Lower-viscosity iodixanol formulations

Claims could focus on a defined iodine concentration, viscosity range, temperature profile, and excipient system. The commercial benefit would be easier administration through power injectors and potentially improved workflow in high-volume imaging centers.

Improved metal-control systems

A formulation using a specific chelator concentration, buffer ratio, or impurity-control profile could support stability claims. The strongest position would link the excipient combination to a defined reduction in degradation products or extended shelf life.

Container and closure systems

Iodixanol products can be differentiated through polymer containers, multilayer bags, prefilled syringes, or low-extractables closures. Patentable subject matter may include:

  • Reduced iodine adsorption
  • Lower extractables and leachables
  • Improved oxygen or moisture barrier properties
  • Compatibility with automated injectors
  • Reduced overfill
  • Better dose accuracy

Ready-to-use imaging kits

A kit combining iodixanol with a prefilled syringe, injector line, warming system, or procedure-specific labeling may generate device and method-of-use protection. The commercial opportunity is strongest where the kit reduces preparation time, medication errors, or waste.

Temperature-management systems

Warming can reduce viscosity, but warming protocols introduce operational and stability requirements. A validated formulation-container-device system that maintains product quality after repeated warming cycles could support differentiated claims.

How strong is the iodixanol patent estate?

The core patent estate is weak as a long-term exclusivity tool because the molecule and original product have been commercially available for decades. The estate can still have value in three areas:

  1. Later-filed formulation improvements.
  2. Manufacturing know-how and impurity control.
  3. Device, packaging, and workflow integration.
Factor Assessment
Composition-of-matter protection Low current value
Original formulation protection Low current value
Process know-how Potentially strong
Excipient innovation Moderate opportunity
Device integration Moderate opportunity
Regulatory complexity High
Biosimilar exposure Not applicable
Generic exposure Real, but constrained by manufacturing economics

Trade secrets may be more important than patents for synthesis conditions, impurity purge strategies, crystallization, purification, sterilization, and analytical release methods. A competitor can often avoid a process patent but still face a long technical-development cycle.

Which companies could compete in iodixanol?

Competition can arise from three groups:

  • Generic injectable manufacturers.
  • Established contrast-media companies.
  • Contract development and manufacturing organizations with sterile injectable capacity.

The principal competitive products are not limited to iodixanol. Iodixanol competes with iohexol, iopamidol, ioversol, and other nonionic iodinated contrast media. Hospitals often evaluate products based on total procedure cost, supply reliability, injector compatibility, clinical protocols, and contracting terms rather than active ingredient alone.

Product Active ingredient Positioning
Visipaque Iodixanol Iso-osmolar, nonionic contrast medium
Omnipaque Iohexol Low-osmolar, nonionic contrast medium
Isovue Iopamidol Low-osmolar, nonionic contrast medium
Optiray Ioversol Low-osmolar, nonionic contrast medium

A new iodixanol entrant would therefore face both molecule-specific generic competition and substitution by other contrast agents.

What licensing and commercial opportunities exist for iodixanol?

Licensing opportunities are most credible in formulation and supply infrastructure rather than in the basic molecule.

Potential transactions include:

  • Regional rights for generic iodixanol injection
  • Supply agreements for iodixanol API
  • Contract manufacturing of sterile vials, bags, or prefilled syringes
  • Co-development of lower-viscosity formulations
  • Injector-compatible packaging
  • Hospital or distributor private-label products
  • Technology licensing for purification and impurity control

A licensee should value the opportunity based on net price, expected tender discounts, manufacturing yield, sterile capacity, and regulatory filing cost. Patent ownership alone is unlikely to support premium economics unless the licensed technology materially reduces cost or enables a differentiated label.

What revenue exposure and launch scenarios exist?

Iodixanol revenue is exposed to generic substitution, hospital tender pricing, and contrast-media procurement consolidation. The highest-risk scenario for the incumbent is a technically equivalent generic with reliable supply and competitive pricing. The most commercially attractive entrant scenario is a product that combines equivalent clinical performance with lower total acquisition or administration cost.

Launch scenario Likely commercial effect
Exact-equivalent generic vial Price pressure and share loss
Generic with broad package sizes Stronger hospital and distributor uptake
Lower-viscosity formulation Differentiated positioning, higher development cost
Prefilled syringe or injector kit Workflow premium, device-regulatory complexity
Regional supply partnership Faster market access, lower infrastructure burden
API-only licensing Limited value unless supply is scarce

Key Takeaways

  • Iodixanol is a mature small-molecule injectable with expired core exclusivity in major markets.
  • The principal commercial asset is formulation and manufacturing execution, not composition-of-matter protection.
  • Tromethamine and calcium disodium edetate support pH control and metal-ion management.
  • Lower viscosity, improved stability, container compatibility, and injector integration are the most credible innovation areas.
  • Biosimilar risk does not apply because iodixanol is a small molecule.
  • Generic-entry risk is real but constrained by sterile manufacturing, API supply, quality control, and hospital contracting.
  • Patent value is most likely to arise from later formulation, packaging, device, and process claims.
  • Licensing opportunities are strongest in regional commercialization, sterile fill-finish, API supply, and differentiated delivery systems.

Frequently Asked Questions

Is iodixanol a biologic requiring a biosimilar pathway?

No. Iodixanol is a synthetic small molecule. A competing U.S. product would generally use the ANDA pathway rather than the biosimilar pathway.

Which iodixanol excipient is most important for stability?

Calcium disodium edetate is important because it controls trace metals that may promote degradation or affect product quality. Tromethamine is important for pH control.

Can a company patent iodixanol with a new excipient?

Yes, but broad claims are difficult for a mature product. A stronger application would link the excipient combination to a measurable technical effect, such as lower viscosity, longer shelf life, reduced degradation, or improved container compatibility.

Is iodixanol more defensible than iohexol against generic competition?

Not on the basis of the active ingredient alone. Iodixanol may face greater formulation and manufacturing complexity because of its high concentration, viscosity, and iso-osmolar design, but those barriers do not create indefinite legal exclusivity.

What is the best commercial entry strategy for an iodixanol competitor?

The lowest-risk strategy is an equivalent sterile injectable with dependable API supply, multiple package sizes, and competitive hospital contracting. A higher-value strategy is a differentiated formulation or delivery system that reduces viscosity, waste, preparation time, or injector-related costs.

References

  1. U.S. Food and Drug Administration. (2023). Visipaque (iodixanol injection) prescribing information.
  2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
  3. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
  4. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary.
  5. European Medicines Agency. (2018). Guideline on the sterilisation of the medicinal product, active substance, excipient and primary container.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.